Narcolepsy Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Veröffentlicht von: precision business insights
Veröffentlicht am: 14.02.2018 07:04
Rubrik: Gesundheit & Medizin

(Presseportal openBroadcast) - Narcolepsy Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023


Narcolepsy is a lifelong sleeping disorder which makes you to feel immensely tired sometimes with uncontrollable sudden sleep attacks in severe cases. It is a disability condition which is characterized by three different symptoms such as excessive daytime cataplexy, sleepiness and irresistible sleep episodes, fluctuating automatic behaviours. Narcolepsy generally begins between 15 to 25 years and it can be evident at any age. Narcolepsy is untreated and undiagnosed in many cases.

Factors that are driving the growth of narcolepsy treatment market are growing prevalence of various sleeping disorders including narcolepsy, increase in awareness about the sleep disorders. Furthermore, increasing demand for advanced diagnostics and therapeutics to treat sleeping disorders and rise in geriatric population. Narcoleptic disorder is proportionately prevalent to Parkinson’s disease, according to the WHO statistics, more than 3 million people are suffering with narcolepsy across the globe. However, stringent regulatory framework, unawareness about the disorder in underdeveloped countries, abuse usage of the drugs, delayed or undiagnosed of the narcolepsy are the few factors which are hampering the growth of narcolepsy treatment market.

A sample of this report is available upon request @

The narcolepsy treatment market is classified on the basis of disorder, drug class, distribution channel, and geography.

Based on type of disorder, the narcolepsy treatment market is segmented into the following:

• Secondary Narcolepsy
• Narcolepsy with cataplexy
• Narcolepsy without cataplexy

Based on drugs, the narcolepsy treatment market is segmented into the following:

• Amphetamines
• Methylphenidate
• Modafinil
• MAO-B Inhibitors (Selegiline)
• Tricyclic Anti-Depressants (TCA)
• Selective Serotonin Reuptake Inhibitors (SSRI)
• Monoamino Oxidase Type-A (MAO-A) inhibitors

Based on distribution channel, the Narcolepsy Treatment Market is segmented into the following:

• Hospital pharmacies
• Retail Pharmacies
• Online Pharmacies

To view TOC of this report is available upon request @

Narcolepsy is the 3rd most common sleeping disorder which affects large group of population. Prevalence rate of narcolepsy is substantially lower in Israel i.e. 1 in 500,000 people and considerably high in Japan i.e. 1 in 600 in comparison with U.S. according to the narcolepsy network. Narcolepsy is not curable but can be treated with drugs like dextroamphetamine, methylphenidate etc. to reduce the sleep attacks. Mergers and acquisitions, collaborations, expansions to untapped geographies are the growth strategies that are adopted by the market players to enhance the market growth and to improve their product portfolio. Several voluntary organizations across the world such as Wake up Narcolepsy, Narcolepsy Network, American Sleep Association, and European Narcolepsy Network are actively involving in spreading the awareness regarding the sleeping disorders and their associated symptoms like EDS, sleep paralysis, and cataplexy.

Need more information about this report @

On the basis of geographical regions, Narcolepsy Treatment Market is classified as into five key regions as Asia- Pacific, North America, Europe, Middle East & Africa and Latin America. Europe narcolepsy treatment market is growing at significant rate owing to the high prevalence of narcolepsy disorder, increasing capital investments and established healthcare infrastructure existence associated with large population target. As per to the estimated data by Narcolepsy UK around 25,000 people are suffering with narcolepsy disorder and about 75% of people are untreated because of undiagnosed and misdiagnosed in U.K. North America holds a significant market share in narcoleptic treatment market owing to the increasing prevalence of the narcolepsy. According to Narcolepsy Network, approximately 1 in 2,000 people in U.S. are suffering with narcolepsy and prevalence of the disorder in North America is about 0.07% and incidence for narcolepsy without cataplexy is 1.37% in 100,000 people and with cataplexy are 0.74 % in 100 people.

Some of the players in narcolepsy treatment market are Arena Pharmaceuticals, Inc.(U.S), Inc., BIOPROJET, Evotec AG (Germany), Graymark Healthcare, Inc. (U.S), Hypnion, Inc. (U.S), Ligand Pharmaceuticals, Inc.(U.S), Teva Pharmaceutical Industries Ltd.(Israel) and Jazz Pharmaceuticals, Inc.,(Ireland).

Get access to full summary @

Toll Free(US): +1-866-598-1553

Bitte beachten Sie, dass für den Inhalt der hier veröffentlichten Meldung nicht openBroadcast verantwortlich ist, sondern der Verfasser der jeweiligen Meldung selbst. AGB | Haftungsausschluss.